Randomized, double-blind study of sonidegib (LDE225) in patients (pts) with locally advanced (La) or metastatic (m) basal-cell carcinoma (BCC)
Michael R. Migden(The University of Texas MD Anderson Cancer Center), Reinhard Dummer(University Hospital of Zurich), Ragini R. Kudchadkar, Alexander Guminski(The University of Sydney), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Uwe Trefzer(Goethe University Frankfurt), R. M. Herd(New South Wales Department of Primary Industries), Manisha Mone, Dalila Sellami(Daiichi Sankyo (United States)), P. Combemale(Centre Léon Bérard), Luc Dirix(European Organisation for Research and Treatment of Cancer), Tingting Yi(Army Medical University), John T. Lear(Salford Royal Hospital), Sven Gogov(Novartis (Switzerland)), Karl D. Lewis(University of Colorado Denver)
Cited by 12
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k